Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid
Status:
Unknown status
Trial end date:
2018-11-01
Target enrollment:
Participant gender:
Summary
Acute lymphoblastic leukemia (ALL) accounts for 30 % of all childhood malignancies. The
patients undergo four phases of treatment, finishing with a late maintenance phase in which
6-mercaptopurine and Methotrexate are essential components. Insufficient treatment intensity
in this phase is associated with increased risk of relapse. Excessive variation in the
bioavailability of 6-mercaptopurine has been observed which can cause both risks of
undertreatment/relapse as well as overtreatment with severe side effects.
In the attempt to achieve individualized 6-mercaptopurine dosing different approaches have
been pursued. Nonetheless variation in bioavailability remains a problem.
Earlier, oral tablets of 50 mg (Purinethol) were the only administration form of
6-mercaptopurine and it was primarily designed for adult patients. Challenges with accurate
dosing and getting the children to swallow the tablets have been a widespread problem,
forcing the caregivers to divide or crush the tablets as well as having to administer
different dosages over 2-3 days. Due to these problems, an oral liquid formulation of
6-mercaptopurine (Xaluprine) has been developed. However this oral liquid has only been
tested on healthy adult volunteers, and not on the target group, childhood patients. This
project will assess the bioavailability and plasma kinetics of oral liquid and tablet
formulation of 6-mercaptopurine in children with acute lymphoblastic leukemia.
The investigators hypothesize to observe comparable plasma kinetics, in children with acute
lymphoblastic leukemia when treated with 6-mercaptopurine in the form of a tablet and oral
liquid formulation, as previously observed in healthy adults.